Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Repertoire Presents Safety, Preliminary Efficacy Data on Autologous Cell Therapy for Solid Tumors

Repertoire Presents Safety, Preliminary Efficacy Data on Autologous Cell Therapy for Solid Tumors

Nov 09, 2020
|
staff reporter

NEW YORK – Cambridge, Massachusetts-based Repertoire Immune Medicines on Monday announced preliminary clinical and biomarker data from an ongoing Phase I/II study of its autologous T-cell therapy, PRIME IL-15, as a treatment for patients with relapsed or refractory metastatic solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

What's Popular?

In Cancer

  1. FDA Approves Daiichi Sankyo, AstraZeneca's Enhertu for Gastric, Gastroesophageal Junction Cancer

  2. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  3. Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

  4. Daiichi Sankyo, AstraZeneca's Enhertu Approved in EU for HER2-Positive Breast Cancer

  5. Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.